UK Cannabis investment company Pharma C has unveiled plans to list on the AQSE Growth Market backed by a £1m fundraise.
Pharma C is an early-stage investor into the medical cannabis industry, with a keen interest in the ancillary services and, an initial focus on UK, Europe and and Israel companies.
In a press release the company says it has ‘unique and early access to vetted, pre-IPO deal flow from a global network of medical cannabis experts’
Its board of directors consists of Sharon Segal, Non-Executive Chairman, Chana Greenberg, Chief Executive Officer, and Gavin Sathianathan, Director of Investment Strategy.
Ms Segal said: “I am delighted to see the company take a huge step in allowing investors to tap into the mounting interest in medical cannabis by listing on the AQSE Growth Market and I am proud of the hard work the team has done to get us to this stage.
“The combined experience of the board and advisory team provides potential investors with the confidence that the business can deliver high returns on investment and identify compelling growth opportunities by utilising both their entrepreneurial experience and knowledge of the medical cannabis sector.”
There are currently around 10 cannabis companies listed on the AQSE including Sativa Wellness and Ananda Developments.
